Bimekizumab for treating active psoriatic arthritis (TA916)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 October 2023
Bimekizumab for treating axial spondyloarthritis (TA918)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 October 2023
Deucravacitinib for treating active psoriatic arthritis TS ID 11981Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Digital platforms for community based self-management of mild to moderate osteoarthritis and joint painStatus:Awaiting developmentProgramme:Medical technologies guidanceExpected publication date: TBC
GID-MT575 GaitSmart rehabilitation exercise programme for gait and mobility issuesStatus:In developmentProgramme:Medical technologies guidanceExpected publication date: 3 April 2024
Radiofrequency denervation for OA shoulder painStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
Sternoclavicular joint replacement for arthritisStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
Tofacitinib for treating active ankylosing spondylitis (TA920)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 October 2023